{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:32:39Z","timestamp":1772681559911,"version":"3.50.1"},"reference-count":71,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>With the availability of BCR::ABL1 targeted tyrosine kinase inhibitors (TKIs), outcomes for most individuals with chronic phase chronic myeloid leukemia (CP-CML) are outstanding, with life expectancy similar to age-matched peers. Treatment-emergent adverse events (TEAEs) impair quality of life and many patients struggle with low-level chronic AEs, which for some individuals impact emotional well-being as well as social and work functioning. An emerging body of data supports that many TEAEs are related to therapy dose and can improve with dose reduction. However, it is critical that dose reductions do not alter current outcomes, especially in the rare patients who are at greater risk of losing response or transforming to acute leukemia. Organizations including the National Comprehensive Cancer Network have begun to address when dose reductions may be considered in patients with CP-CML. In this manuscript, we review retrospective and prospective data reporting outcomes in patients after dose reduction and review data supporting lower dose preemptive dosing in first-line and later-line therapy. Switching therapy for intolerance can result in improvements in symptoms and limit toxicity, but other TEAEs may occur. Additionally, emerging therapeutics such as the new class of BCR::ABL1 allosteric inhibitors are under evaluation with a goal of improving tolerability. However, with many TKIs on the cusp of becoming generic, dose reduction becomes an appealing and important cost-effective strategy to minimize TEAEs and improve quality of life while preserving outstanding outcomes in CP-CML.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7044","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:34:20Z","timestamp":1731504860000},"source":"Crossref","is-referenced-by-count":4,"title":["Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When"],"prefix":"10.6004","volume":"22","author":[{"given":"Vivian G.","family":"Oehler","sequence":"first","affiliation":[{"name":"Division of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle WA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Pharmacy, University of Washington Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Siu","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Pharmacy, University of Washington Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miryoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Pharmacy, University of Washington Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Signorelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Bell","sequence":"additional","affiliation":[{"name":"Leukemia Department, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Leukemia Department, Massachusetts General Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Clin Oncol","first-page":"2851","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower H","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW,  Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34:2851\u20132857."},{"key":"B2","series-title":"N Engl J Med","first-page":"994","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien SG","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA,  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994\u20131004."},{"key":"B3","series-title":"N Engl J Med","first-page":"2408","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker BJ","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG,  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408\u20132417."},{"key":"B4","series-title":"N Engl J Med","first-page":"917","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F,  Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917\u2013927."},{"key":"B5","series-title":"N Engl J Med","first-page":"2260","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A,  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260\u20132270."},{"key":"B6","series-title":"J Clin Oncol","first-page":"2333","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM,  Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333\u20132340."},{"key":"B7","series-title":"Leukemia","first-page":"440","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA,  Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35:440\u2013453."},{"key":"B8","series-title":"Leukemia","first-page":"1825","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D,  Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia 2022;36:1825\u20131833."},{"key":"B9","series-title":"Blood","first-page":"393","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J,  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018;132:393\u2013404."},{"key":"B10","series-title":"Blood","first-page":"2042","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes J","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E,  Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 2021;138:2042\u20132050."},{"key":"B11","series-title":"Blood Rev","first-page":"100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia \u2014 what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton JH","year":"2022","unstructured":"Lipton JH, Brummendorf TH, Gambacorti-Passerini C,  Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia \u2014 what to look for when treatment-free remission is not an option. Blood Rev 2022;56:100968."},{"key":"B12","series-title":"Blood","first-page":"4554","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace F","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M,  Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554\u20134560."},{"key":"B13","series-title":"Leuk Res","first-page":"206","article-title":"Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review","volume":"37","author":"Efficace F","year":"2013","unstructured":"Efficace F, Cardoni A, Cottone F,  Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013;37:206\u2013213."},{"key":"B14","series-title":"Cancer","first-page":"2228","article-title":"Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib","volume":"124","author":"Efficace F","year":"2018","unstructured":"Efficace F, Castagnetti F, Martino B,  Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer 2018;124:2228\u20132237."},{"key":"B15","series-title":"Curr Hematol Malig Rep","first-page":"491","article-title":"Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions","volume":"16","author":"Schoenbeck KL","year":"2021","unstructured":"Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep 2021;16:491\u2013499."},{"key":"B16","article-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 2.2024","author":"Shah NP","unstructured":"Shah NP, Bhatia R, Altman JK,  NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 2.2024. Accessed December 5, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B17","series-title":"Leukemia","first-page":"966","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT,  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966\u2013984."},{"key":"B18","series-title":"JAMA Oncol","first-page":"42","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah E","year":"2021","unstructured":"Atallah E, Schiffer CA, Radich JP,  Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol 2021;7:42\u201350."},{"key":"B19","series-title":"J Natl Cancer Inst","first-page":"160","article-title":"Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors","volume":"114","author":"Schoenbeck KL","year":"2022","unstructured":"Schoenbeck KL, Atallah E, Lin L,  Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst 2022;114:160\u2013164."},{"key":"B20","series-title":"Leukemia","first-page":"1648","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann JL","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M,  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016;30:1648\u20131671."},{"key":"B21","series-title":"Cancer Sci","first-page":"1071","article-title":"Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study","volume":"103","author":"Ohnishi K","year":"2012","unstructured":"Ohnishi K, Nakaseko C, Takeuchi J,  Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 2012;103:1071\u20131078."},{"key":"B22","series-title":"Ann Hematol","first-page":"749","article-title":"Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission","volume":"86","author":"Carella AM","year":"2007","unstructured":"Carella AM, Lerma E. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol 2007;86:749\u2013752."},{"key":"B23","series-title":"Acta Haematol","first-page":"219","article-title":"Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area","volume":"118","author":"Park SJ","year":"2007","unstructured":"Park SJ, Choi IK, Seo HY,  Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol 2007;118:219\u2013221."},{"key":"B24","series-title":"Ann Hematol","first-page":"81","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes F","year":"2017","unstructured":"Cervantes F, Correa JG, Perez I,  Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol 2017;96:81\u201385."},{"key":"B25","series-title":"Lancet Haematol","first-page":"e310","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non- randomised, phase 2 trial","volume":"4","author":"Clark RE","year":"2017","unstructured":"Clark RE, Polydoros F, Apperley JF,  De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non- randomised, phase 2 trial. Lancet Haematol 2017;4:e310\u2013316."},{"key":"B26","series-title":"Lancet Haematol","first-page":"e375","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark RE","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF,  De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol 2019;6:e375\u2013383."},{"key":"B27","series-title":"Blood","first-page":"5138","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo D","year":"2013","unstructured":"Russo D, Martinelli G, Malagola M,  Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 2013;121:5138\u20135144."},{"key":"B28","series-title":"Cancer Med","first-page":"1726","article-title":"Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: first interim analysis of OPTkIMA study","volume":"10","author":"Malagola M","year":"2021","unstructured":"Malagola M, Iurlo A, Abruzzese E,  Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: first interim analysis of OPTkIMA study. Cancer Med 2021;10:1726\u20131737."},{"key":"B29","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"323","article-title":"The Italian multicentric randomized OPTkIMA trial on fixed vs progressive intermittent TKI therapy in CML elderly patients: 3-years of molecular response and quality of life monitoring after completing the treatment plan","volume":"24","author":"Malagola M","year":"2024","unstructured":"Malagola M, Iurlo A, Bucelli C,  The Italian multicentric randomized OPTkIMA trial on fixed vs progressive intermittent TKI therapy in CML elderly patients: 3-years of molecular response and quality of life monitoring after completing the treatment plan. Clin Lymphoma Myeloma Leuk 2024;24:323\u2013331."},{"key":"B30","article-title":"Prescribing information. Bristol Myers Squibb; 2023","author":"Dasatinib tablets","unstructured":"Dasatinib tablets. Prescribing information. Bristol Myers Squibb; 2023. Accessed October 15, 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021986s027lbl.pdf"},{"key":"B31","series-title":"Cancer","first-page":"377","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka K","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL,  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377\u2013386."},{"key":"B32","series-title":"Haematologica","first-page":"93","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Laneuville P, Rousselot P,  Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 2019;104:93\u2013101."},{"key":"B33","series-title":"Am J Hematol","first-page":"869","article-title":"Dasatinib in imatinib-resistant or-intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah NP","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C,  Dasatinib in imatinib-resistant or-intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016;91:869\u2013874."},{"key":"B34","series-title":"Eur J Haematol","first-page":"243","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen H","year":"2015","unstructured":"Hjorth-Hansen H, Stenke L, Soderlund S,  Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2015;94:243\u2013250."},{"key":"B35","series-title":"Br J Haematol","first-page":"303","article-title":"Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"150","author":"Santos FP","year":"2010","unstructured":"Santos FP, Kantarjian H, Fava C,  Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 2010;150:303\u2013312."},{"key":"B36","article-title":"Prescribing information. Novartis Pharmaceuticals Corporation; 2024","author":"Nilotinib capsules","unstructured":"Nilotinib capsules. Prescribing information. Novartis Pharmaceuticals Corporation; 2024. Accessed March 15, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022068s041lbl.pdf"},{"key":"B37","series-title":"Blood Adv","first-page":"1084","article-title":"The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia","volume":"3","author":"Minson AG","year":"2019","unstructured":"Minson AG, Cummins K, Fox L,  The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. Blood Adv 2019;3:1084\u20131091."},{"key":"B38","series-title":"Int J Cardiol","first-page":"124","article-title":"Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention","volume":"288","author":"Caocci G","year":"2019","unstructured":"Caocci G, Mulas O, Bonifacio M,  Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol 2019;288:124\u2013127."},{"key":"B39","series-title":"Leukemia","first-page":"1044","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP,  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044\u20131054."},{"key":"B40","series-title":"Blood","first-page":"318","article-title":"Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED)","volume":"130(Suppl)","author":"Rea D","year":"2017","unstructured":"Rea D, Cayuela JM, Duluoq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood 2017;130(Suppl):Abstract 318."},{"key":"B41","series-title":"Blood","first-page":"4567","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes JE","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH,  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567\u20134576."},{"key":"B42","series-title":"J Clin Oncol","first-page":"231","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW,  Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018;36:231\u2013237."},{"key":"B43","article-title":"Prescribing information. Pfizer Inc.; 2023","author":"Bosutinib tablets","unstructured":"Bosutinib tablets. Prescribing information. Pfizer Inc.; 2023. Accessed October 15, 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203341s024lbl.pdf"},{"key":"B44","series-title":"J Clin Oncol","first-page":"7039","article-title":"Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib","volume":"39","author":"Deininger MW","year":"2021","unstructured":"Deininger MW, Br\u00fcmmendorf TH, Milojkovic D,  Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib. J Clin Oncol 2021;39:7039\u20137039."},{"key":"B45","series-title":"Leuk Res","first-page":"106690","article-title":"Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2013positive leukemias","volume":"111","author":"Kota V","year":"2021","unstructured":"Kota V, Brummendorf TH, Gambacorti-Passerini C,  Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2013positive leukemias. Leuk Res 2021;111:106690."},{"key":"B46","article-title":"Prescribing information. Takeda Pharmaceuticals; 2022","author":"Ponatinib tablets","unstructured":"Ponatinib tablets. Prescribing information. Takeda Pharmaceuticals; 2022. Accessed October 15, 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203469s035lbl.pdf"},{"key":"B47","series-title":"Leuk Res","first-page":"84","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer DJ","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M,  Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res 2016;48:84\u201391."},{"key":"B48","series-title":"J Hematol Oncol","first-page":"1","article-title":"Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee","volume":"15","author":"Januzzi JL","year":"2022","unstructured":"Januzzi JL, Garasic JM, Kasner SE,  Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol 2022;15:1."},{"key":"B49","series-title":"Leukemia","first-page":"475","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Apperley J, Cortes J,  Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 2024;38:475\u2013481."},{"key":"B50","series-title":"Neoplasia","first-page":"536","article-title":"Frontline dasatinib treatment in a \u201creal-life\u201d cohort of patients older than 65 years with chronic myeloid leukemia","volume":"18","author":"Latagliata R","year":"2016","unstructured":"Latagliata R, Stagno F, Annunziata M,  Frontline dasatinib treatment in a \u201creal-life\u201d cohort of patients older than 65 years with chronic myeloid leukemia. Neoplasia 2016;18:536\u2013540."},{"key":"B51","series-title":"Leuk Lymphoma","first-page":"2093","article-title":"Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase","volume":"55","author":"Chuah CT","year":"2014","unstructured":"Chuah CT, Nakamae H, Shen ZX,  Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma 2014;55:2093\u20132100."},{"key":"B52","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e521","article-title":"Appropriate starting dose of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia","volume":"21","author":"Shin H","year":"2021","unstructured":"Shin H, Ha JE, Zang DY,  Appropriate starting dose of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2021;21:e521\u2013529."},{"key":"B53","series-title":"Cancer","first-page":"67","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi K","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J,  Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2020;126:67\u201375."},{"key":"B54","series-title":"Cancer","first-page":"2740","article-title":"Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi K","year":"2018","unstructured":"Naqvi K, Jabbour E, Skinner J,  Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2018;124:2740\u20132747."},{"key":"B55","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"742","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos G","year":"2023","unstructured":"Gener-Ricos G, Haddad FG, Sasaki K,  Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk 2023;23:742\u2013748."},{"key":"B56","series-title":"Am J Hematol","first-page":"1413","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG,  Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol 2022;97:1413\u20131418."},{"key":"B57","series-title":"Lancet Haematol","first-page":"e902","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai K","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T,  Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2021;8:e902\u2013911."},{"key":"B58","series-title":"Med Oncol","first-page":"38","article-title":"Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase","volume":"35","author":"Tokuhira M","year":"2018","unstructured":"Tokuhira M, Kimura Y, Sugimoto K,  Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol 2018;35:38."},{"key":"B59","series-title":"Leuk Res","first-page":"109","article-title":"Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study","volume":"67","author":"Hiwase D","year":"2018","unstructured":"Hiwase D, Tan P, D\u2019Rozario J,  Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study. Leuk Res 2018;67:109\u2013115."},{"key":"B60","series-title":"J Hematol Oncol","first-page":"143","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ,  Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 2018;11:143."},{"key":"B61","series-title":"Blood","first-page":"496","article-title":"Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors","volume":"134","author":"Castagnetti F","year":"2019","unstructured":"Castagnetti F, Gugliotta G, Bocchia M,  Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood 2019;134:496."},{"key":"B62","series-title":"HemaSphere","first-page":"593","article-title":"P698: bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the best study","volume":"6","author":"Castagnetti F","year":"2022","unstructured":"Castagnetti F, Bocchia M, Abruzzese E,  P698: bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the best study. HemaSphere 2022;6:593\u2013594."},{"key":"B63","series-title":"Ann Hematol","first-page":"2741","article-title":"Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) study","volume":"102","author":"Isfort S","year":"2023","unstructured":"Isfort S, Manz K, Teichmann LL,  Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) study. Ann Hematol 2023;102:2741\u20132752."},{"key":"B64","series-title":"Br J Haematol","first-page":"452","article-title":"Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years","volume":"189","author":"Dulucq S","year":"2020","unstructured":"Dulucq S, Astrugue C, Etienne G,  Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol 2020;189:452\u2013468."},{"key":"B65","series-title":"Blood Adv","first-page":"3034","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot P","year":"2020","unstructured":"Rousselot P, Loiseau C, Delord M,  Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv 2020;4:3034\u20133040."},{"key":"B66","series-title":"Br J Haematol","first-page":"393","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot P","year":"2021","unstructured":"Rousselot P, Mollica L, Guilhot J,  Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol 2021;194:393\u2013402."},{"key":"B67","series-title":"Blood Cancer J","first-page":"144","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian A","year":"2022","unstructured":"Bidikian A, Kantarjian H, Jabbour E,  Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J 2022;12:144."},{"key":"B68","series-title":"Leukemia","first-page":"2242","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Schonfeld L","year":"2022","unstructured":"Schonfeld L, Rinke J, Hinze A,  ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia 2022;36:2242\u20132249."},{"key":"B69","series-title":"Haematologica","first-page":"2380","article-title":"Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention","volume":"108","author":"Shanmuganathan N","year":"2023","unstructured":"Shanmuganathan N, Wadham C, Shahrin N,  Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica 2023;108:2380\u20132395."},{"key":"B70","series-title":"Hemasphere","first-page":"60","article-title":"Quebec CML research group analysis of treatment patterns in chronic myelogenous leukemia: switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment","volume":"6","author":"Busque L","year":"2022","unstructured":"Busque L, Harnois M, Delage R,  Quebec CML research group analysis of treatment patterns in chronic myelogenous leukemia: switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment. Hemasphere 2022;6:60\u201361."},{"key":"B71","series-title":"J Natl Compr Canc Netw","first-page":"e237116","article-title":"Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors","volume":"22","author":"Haddad FG","year":"2024","unstructured":"Haddad FG, Kantarjian H. Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors. J Natl Compr Canc Netw 2024;22:e237116."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/9\/article-e247044.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/9\/article-e247044.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/9\/article-e247044.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:34:20Z","timestamp":1731504860000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/9\/article-e247044.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":71,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7044","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}